90301-59-0

Upstream product

• 90301-69-2 5-(2-chloroethyl)-1-(2-deoxy-3,5-di-O-p-toluoyl-β-D-erythro-pentofuranosyl)-1H,3H-pyrimidine-2,4-dione 
• 97975-00-3 5-(2-deoxy-β-D-erythro-pentofuranosyl)-2,3-dihydro-5H-furano<2,3-d>pyrimidin-6-one 
• 3056-12-0 2-deoxy-3,5-di-O-(p-toluoyl)-α-D-erythropentofuranosyl chloride 
• 23956-12-9 5-(2-hydroxyethyl)-uracil 
• 90301-68-1 5-(2-Chloroethyl)uracil 
• 90301-60-3 1-((2R,4S,5R)-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-5-(2-hydroxyethyl)pyrimidine-2,4(1H,3H)-dione 

Downstream Products

• 115365-33-8 5-(2-chloroethyl)-5'-(4,4'-dimethoxytrityl)-2'-deoxyuridine 
• 115365-30-5 <(benzyloxy)carbonyl>phosphonic acid 5-(2-chloroethyl)-2'-deoxyuridin-5'-yl ester 
• 115365-40-7 <5-(2-chloroethyl)-2'-deoxyuridin-5'-yl>(phenylamino)phosphinecarboxylic acid ethyl ester oxide 

Relevant academic research and scientific papers

Syntheses of 5-(2-radiohaloethyl)- and 5-(2-radiohalovinyl)-2′-deoxyuridines. Novel types of radiotracer for monitoring cancer gene therapy with PET

Syntheses of 5-(2-[18F]fluoroethyl)- (1) 5-(2-[80Br] bromoethyl), (2), undeprotected (E)-5-(2-[18F]fluorovinyl)- (3) and (E)-5-(2-[80Br]bromovinyl),2′-deoxyuridines (4) as the tracers for monitoring cancer gene therapy with positron emission tomography were described. Decay corrected radiochemical yield and synthesis time including labeling and HPLC purification from end of bombardment for 1 was 9.5% and 2 hours, respectively; yield and time for 2 was 16% and 2 hours, respectively. Chemical (approximate to radiochemical) yield and time for synthesis of 3 was 7.5% and 7 minutes, respectively. Radiochemical yield and synthesis time including labeling and HPLC purification of an analytical sample of 4 was 60% and 30 minutes, respectively. Both 2 and 4 received the side reactions during HPLC purification, i.e. ring closure and cleavage of glycosidic bond, respectively. Application of 2 and 4 needed to be confirmed by in vitro or in vivo experiments. Radiochemical yield of 1 could be optimized by employing a modified protocol for preparation of its precursor. The preparation of fluorovinyl counterparts had demonstrated the potential utility of the stannane, 3-tolyl-3′,5′-di-O-acetyl-(E)-5-(2-stannylvinyl)- 2′-deoxyuridine 7. Copyright

Nucleoside analogue phosphates for topical use

Compositions for topical use in herpes virus infections comprising anti-herpes nucleoside analogue phosphate esters, such as acyclovir monophosphate, acyclovir diphosphate, and acyclovir triphosphate which show increased activity against native strains of herpes virus as well as against resistant strains, particularly thymidine kinase negative strains of virus. Also disclosed are methods for treatment of herpes infections with nucleoside phosphates. Anti-herpes nucleoside analogues phosphate esters include the phosphoramidates and phosphothiorates, as well as polyphosphates comprising C and S bridging atoms.

5-(Haloalkyl)-2'-deoxyuridines: A Novel Type of Potent Antiviral Nucleoside Analogue

Syntheses of 5-(2-haloethyl)-2'-deoxyuridines, 5-(3-chloropropyl)-2'-deoxyuridines, and 5-(2-chloroethyl)-2'-deoxycytidine are described.The antiviral activities of these compounds were determined in cell culture against herpes simplex virus types 1 and 2